• OTS
  • February 16, 2021
SHARE
Post Views: 441

Zanardi TA, Korbmacher B, Boone L, Engelhardt JA, Wang Y, Burel S, Prill B, Aghajan M, Guo S, Henry SP.

J Pharmacol Exp Ther. 2021 Jan 11:JPET-AR-2020-000222

Pubmed

Related articles

Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma

Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma

April 23rd, 2021
Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome

Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome

April 23rd, 2021
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

April 23rd, 2021
Antisense oligonucleotide therapy in a humanized mouse model of MECP2 duplication syndrome

Antisense oligonucleotide therapy in a humanized mouse model of MECP2 duplication syndrome

April 23rd, 2021
Sequence-specific 2′-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates

Sequence-specific 2′-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates

March 15th, 2021
Binding of phosphorothioate oligonucleotides with RNase H1 can cause conformational changes in the protein and alter the interactions of RNase H1 with other proteins

Binding of phosphorothioate oligonucleotides with RNase H1 can cause conformational changes in the protein and alter the interactions of RNase H1 with other proteins

March 15th, 2021